Categories: Noveltuberculosis

A novel tuberculosis regimen shortens treatment course for patients

Dr. Susan Dorman, pictured here in her laboratory at the Medical University of South Carolina, led the trial of the novel TB treatment. Credit: Sarah Pack, Medical University of South Carolina.

Tuberculosis (TB) is a deadly infection that occurs in every part of the world. The standard treatment for TB, a six-month multidrug regimen, has not changed in more than 40 years. Patients can find it difficult to complete the lengthy regimen, making it more likely that treatment resistance will develop.

A research team led by a Medical University of South Carolina (MUSC) investigator reports in the May 6 issue of the New England Journal of Medicine that a four-month treatment regimen using rifapentine is effective for treating TB. Shortening the treatment duration is an important step toward increased .

In 2019 alone, 1.4 million people died from TB worldwide. TB is caused by a bacterial infection that attacks the lungs of those infected. The World Health Organization estimates that one-quarter of the world’s population has a TB infection, and those individuals will have a 5% to 10% lifetime risk of developing full TB disease. Individuals with compromised immune systems, such as people with HIV, have a much higher risk of developing TB.

“TB often affects adults in the prime of their lives,” said Susan Dorman, M.D., a professor in the College of Medicine at MUSC and first author of the study. “This disease and treatment can disrupt lives and pull families into poverty.”

While TB is curable and preventable, multidrug-resistant TB remains a top public health threat. Resistance occurs when bacteria develop the ability to defeat drugs that are designed to kill them. When one bacterium in the colony figures out how to defeat a particular , it can quickly communicate out those instructions to neighboring bacteria, similar to sending out a group text message.

The current treatment for those with an active TB infection is a multidrug regimen over the course of six to nine months. Because different antibiotics use different mechanisms to defeat bacteria, TB is treated with several antibiotics at once to decrease the chances that the bacteria will become resistant to the drugs.

“Patient adherence to the taxing drug regimen has been a huge problem worldwide, and it is the main factor that has given rise to the very drug-resistant forms of TB that are much more toxic, expensive and time-consuming to treat,” said Dorman.

Reducing the length of time needed to treat tuberculosis has long been an important public health goal. The more patients who complete their treatments for TB, the less likely it is for bacteria to escape with knowledge to defeat a particular drug and continue the group message thread to other bacteria.

“Shortening the treatment time improves adherence, decreases costs to programs and decreases the burdens on patients themselves,” explained Dorman.

Dorman and her team at MUSC worked with both a Centers for Disease Control and Prevention (CDC) and a National Institutes of Health trials group to find a way to shorten the overall duration of treatment needed to cure the disease completely.

The team focused on a drug called rifapentine. This drug is similar to the antibiotic used in the current TB treatment protocol but remains effective in the body for longer periods of time. Over the course of 15 years, Dorman and her team performed preclinical and early phase to determine how best to use this drug. They determined what dosage to give, how often the drug can be administered and what other antibiotics to pair with it. They then launched a worldwide phase III study with the TB Trials Consortium and the AIDS clinical trial group.

Patients with active TB infections were treated with one of two four-month rifapentine-based regimens or the standard six-month regimen. They were followed for 12 months. The results of the trial revealed that the four-month regimen containing rifapentine and another antibiotic, moxifloxacin, worked just as well as the six-month regimen. It was also safe and well-tolerated by the patients.

Dorman and her team hope these results will change how TB is currently being treat

Read More

News Bot

Published by
News Bot

Recent Posts

Quade Cooper denied Australian citizenship despite playing for national rugby team

Quade Cooper denied Australian citizenship despite playing for national rugby team  BBC NewsFormer Wallabies fly-half Quade…

18 mins ago

An Art Deco Delight Along Australia’s Yarra River Asks $12 Million

An Art Deco Delight Along Australia’s Yarra River Asks $12 Million  Forbes

18 mins ago

The 15 least popular Australian baby names in 2021

The 15 least popular Australian baby names in 2021

18 mins ago

How to watch Australia v Japan | Matildas

How to watch Australia v Japan | Matildas  Matildas

18 mins ago

Home, sweet, roam

Tuesday 13 July, 2021 Renting out a motorhome or campervan with PaulCamper couldn’t be easierRange…

18 mins ago

Netflix will co-produce a documentary about SpaceX’s Inspiration4 mission

Home News Entertainment "Countdown: Inspiration4 Mission to Space" is scheduled to premiere Sept. 6, 2021.…

20 mins ago